Company / Financials
Arbutus Biopharma Corp Financials
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$14.1M
FY2025 · +128.2% YoY
Net Income
-$33.5M
FY2025 · +52.1% YoY
Profit Margin
-237.9%
FY2025 · net income / revenue
ROE
-43.8%
FY2025 · return on equity
Total Assets
$94.6M
FY2025
Total Debt
$0
0.00x debt/equity
Equity
$76.6M
FY2025
ROA
-35.4%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -11.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$14.1M+128.2% YoYNet Income HistoryProfit after all expenses and taxes-$33.5M+52.1% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$38.2M+50.0% YoYSG&A Expense HistorySelling, general, and administrative expenses$15.9M-28.1% YoYR&D Expense HistoryResearch and development spending$25.2M-53.3% YoYInterest Expense HistoryCost of borrowing and debt obligations$459.0KIncome Tax HistoryTotal income tax expense$0EPS (Basic) HistoryBasic earnings per share-$0.38+13.6% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$0.38+13.6% YoYShares Outstanding HistoryWeighted average diluted shares outstanding190.0M+11.8% YoY